Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries

Efthymiadou, Olina (2022) Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries. European Journal of Health Economics. ISSN 1618-7598

Text (Efthymiadou_health-technology-assessment-criteria--published) - Published Version Available under License Creative Commons Attribution. Download (956kB)

• Scopus publication
• Author

Abstract

Background: Managed entry agreements (MEAs) continue to emerge in health technology assessment (HTA)-based decision-making, to address evidentiary uncertainties arising therein. Evidence on the HTA criteria that influence MEAs' uptake remains scarce. This study explores the HTA criteria that determine (i) if an HTA funding decision will be listed with conditions (LWC) other than a MEA, or with a MEA as a condition (LWCMEA), and ii) the MEA type implemented (i.e., financial, outcomes based, or combination). Methods: HTA reports of all oncology medicines approved since 2009 in Australia, England, Scotland, and Sweden were searched to capture the clinical/economic evidence uncertainties raised in the decision-making process, the Social Value Judgements (SVJs) considered therein and the final coverage decision. Binary and multinomial logit models captured the probability (odds ratio (OR)) of a coverage decision being LWCMEA vs. LWC, and of the MEA being financial, outcomes based, or combination, based on the HTA criteria studied. Results: 23 (12%) LWC and 163 (88%) LWCMEA decisions were identified; 136 (83.4%) comprised financial, 10 (6.2%) outcomes based and 17 (10.4%) combination MEAs. LWCMEA decisions were driven by economic model utilities' uncertainties (7.16 < OR < 26.7, p <.05), and the innovation (8.5 < OR < 11.7, p <.05) SVJ. Outcomes based contracts were influenced by clinical evidence (OR = 69.2, p <.05) and relevance to clinical practice (OR = 26.4, p <.05) uncertainties, and rarity (OR = 46.2, p <.05) and severity (OR = 23.3, p <.05) SVJs. Financial MEAs were influenced by innovation (8.9 < OR < 9.3, p <.05) and societal impact (OR = 17.7, p <.0001) SVJs. Conclusions: This study provides an empirical framework on the HTA criteria that shape payers' preferences in funding with MEAs, when faced with uncertainty.

Item Type:	Article
Official URL:	https://www.springer.com/journal/10198
Additional Information:	© 2022 The Author
Divisions:	LSE Health
Subjects:	R Medicine > RA Public aspects of medicine R Medicine > RM Therapeutics. Pharmacology
Date Deposited:	22 Sep 2022 17:27
Last Modified:	16 Nov 2024 21:54
URI:	http://eprints.lse.ac.uk/id/eprint/116668

Actions (login required)

View Item